3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
21
Triple Negative Breast Neoplasms
12
Inflammatory Breast Neoplasms
2
Carcinoma, Adenoid Cystic
2
Resectable HER2-positive Breast Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Hodgkin Disease
1
HR+/HER2- Breast Cancer
1
Epstein-Barr Virus Infections
1
Down Syndrome
1
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
1
Interventions
pembrolizumab
2
atezolizumab
2
Paclitaxel
2
Carboplatin
2
veliparib
1
sintilimab
1
pertuzumab
1
pemigatinib
1
olaparib
1
ivosidenib
1
ipatasertib
1
entrectinib
1
cobimetinib
1
alectinib
1
Whole Genome Sequencing
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Taxes
1
Surveys and Questionnaires
1
Specimen Handling
1
Sequence Analysis, RNA
1
Radiosurgery
1
Magnetic Resonance Spectroscopy
1
HhAntag691
1
Genetic Testing
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
FAPI-46
1
Erlotinib Hydrochloride
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms, Unknown Primary
×
Epirubicin
×
1 year
×
Clear all
No trials found.